DPYD PharmaKitDx – Advancing Personalized Cancer Treatment
DPYD PharmaKitDx is a genetic testing solution designed to identify patients with dihydropyrimidine dehydrogenase (DPD) deficiency, affecting the metabolism of certain cancer chemotherapy drugs.
This test is also available as a Stripassay 5FU DPYD (PGX-5FU XL) from our esteemed partner Viennalab.
DPYD PharmaKitDx is a genetic testing solution that identifies patients with dihydropyrimidine dehydrogenase (DPD) deficiency. DPD is an essential enzyme responsible for metabolizing fluoropyrimidine drugs used in cancer chemotherapy, like 5-fluorouracil (5-FU) and capecitabine.
Certain individuals carry genetic variations in the DPYD gene, leading to reduced or absent DPD activity. This condition puts them at a higher risk of severe and potentially life-threatening side effects when receiving standard doses of fluoropyrimidine medications. Early detection of DPD deficiency allows healthcare professionals to tailor treatments and make informed decisions for each patient’s optimal outcomes.
Using DPYD PharmaKitDx is straightforward for researchers and lab technicians. The kit provides all necessary materials and detailed instructions to collect a patient’s DNA sample, usually through blood or saliva. Within a short time, the lab delivers comprehensive genetic testing results, indicating the patient’s DPD status. Based on these results, clinicians can customize the treatment plan for maximum safety and efficacy.
DPYD PharmaKitDx represents a significant stride towards personalized medicine in oncology. As pharmacogenomics advances, similar genetic testing kits may emerge for other drugs and conditions, further enhancing patient outcomes and improving quality of life.
Specifications:
Subscribe to our newsletter.